Top 3 High Growth Stocks to Buy Now (AI, E-Commerce & Biotech)

In today’s market, finding high-growth stocks requires identifying companies that sit at the center of powerful long-term trends such as artificial intelligence, digital commerce, and breakthrough healthcare innovation. These three companies operate in different sectors, but they share strong financial performance and long-term growth potential. In this article, we will dive into their financial performance, growth prospects, and the risks to consider.

1. Broadcom

Broadcom has emerged as one of the most critical enablers of the artificial intelligence revolution. The company designs and supplies semiconductor and infrastructure software solutions that power data centers, networking systems, and cloud computing platforms. What makes Broadcom particularly compelling is its exposure to custom AI chips (ASICs), which are increasingly in demand as hyperscalers like Meta and Alphabet build out their own AI infrastructure.

Broadcom Financial Performance

Broadcom’s Q1 2026 results demonstrate exceptional financial strength and continued momentum across its business segments. For the quarter ending February 2026, the company reported revenue of $19.31 billion, representing a 29.47% year-over-year increase. Earnings per share (EPS) came in at $1.50, marking a 31.58% increase year over year.

Looking at a trailing twelve months TTM basis, Broadcom generated $68.28 billion in revenue, up 25.22%, while EPS surged to $5.12, a remarkable 146.15% increase.

Free cash flow generation remains one of Broadcom’s strongest attributes. The company delivered free cash flow per share of $5.94 TTM, representing a 36.87% increase.

Over the past five years, Broadcom has delivered consistent growth with strong margins in net income and free cash flow. Driven by AI chip demand, its high double-digit growth is likely to persist.

Broadcom Fiscal 2026 Financial Forecast

Looking ahead, analyst expectations remain highly optimistic. Revenue for full-year 2026 is projected to reach $104.36 billion, implying 63.36% growth, while non Gap EPS is expected to hit $11.43, up 67.53%. Wallstreet analysts currently assign a Strong Buy rating, with an average price target of $475.49, indicating a 12.47% upside from current levels. The most bullish target stands at $630, implying a potential 49% upside, underscoring the belief that the company’s growth trajectory is far from over.

AVGO Stock Price Performance and Valuation

Broadcom’s stock performance over the past year has been nothing short of extraordinary. At a current price of $422.76 per share, the stock has surged 124.7% over the past year, significantly outperforming the S&P 500, which gained 30.6% during the same period.

The long-term performance is even more impressive. Over the past five years, Broadcom has delivered a total return of 806.9%, compared to the S&P 500’s 71.4% gain. This level of outperformance places Broadcom among the elite compounders in the market.

Based on Fiscal.ai data, the forward P/E valuation is above its historical average. However, despite this premium, Broadcom is projected to grow its revenue and EPS by more than 60% this year, which still makes its valuation reasonable.

Broadcom Growth Potential

Broadcom growth potential remains strong, driven by several factors.

1. Explosive AI Semiconductor Demand and Custom XPU Ramp

Broadcom reported strong AI semiconductor revenue of $8.4 billion in Q1 2026, rising 106% year over year and surpassing expectations, driven by demand for custom AI accelerators from five hyperscale customers. Its custom XPU segment surged 140%, with Q2 AI revenue projected at $10.7 billion, reflecting accelerating deployments and reinforcing its key role in long-term AI infrastructure growth.

2. AI Networking Acceleration and Ethernet Leadership

AI networking revenue was a major driver of Broadcom’s semiconductor growth, which rose 52% year over year to $12.5 billion, with networking increasing 60% in Q1 and set to accelerate in Q2. Products like Tomahawk 6 switches and advanced SerDes solutions support AI cluster connectivity, benefiting from high-bandwidth Ethernet adoption and expanding Broadcom’s diversified AI exposure.

3. Capital Returns, Backlog Visibility, and Multi-Year Outlook

Broadcom returned $10.9 billion to shareholders in Q1 through dividends and repurchases, supported by $8.01 billion in free cash flow which is 41% of revenue. With a substantial AI backlog and visibility toward over $100 billion in AI chip revenue by fiscal 2027, secured supply capacity through 2028 supports disciplined execution and partnerships, driving sustained double-digit growth potential in the years ahead.

Risks to Consider

Although Broadcom’s growth remains strong, we should be mindful of potential risks.

1. Customer Concentration Risk in AI Segment

Broadcom derives a significant portion of its AI semiconductor revenue from a small number of hyperscale cloud customers, such as major tech giants. Any slowdown in their capital expenditure, shift toward in-house chip development, or delay in deployment could trigger sharp revenue misses and pressure profitability. This concentration amplifies volatility, as losing even one large client might create noticeable gaps in the high-growth AI backlog.

2. Geopolitical and Trade Tensions, Especially with China

With notable revenue exposure to China (around 17% in recent fiscal periods), Broadcom faces risks from U.S. tariffs on AI chips, Chinese directives to phase out foreign software like VMware in state enterprises, and retaliatory measures. These could result in lost sales, margin compression on exports, and broader supply chain disruptions amid escalating U.S.-China decoupling.

3. High Valuation and Slowdown in AI Spending

Trading at elevated multiples, Broadcom's stock leaves limited room for error if hyperscaler AI capex moderates due to economic uncertainty, ROI concerns, or technological shifts. A broader slowdown in AI infrastructure investments, combined with cyclical semiconductor dynamics and debt from acquisitions, could lead to valuation compression and stock volatility.

Despite this, Broadcom’s strong projected financial performance and AI demand still leave significant room for potential upside.

2. MercadoLibre

MercadoLibre is often referred to as the “Amazon of Latin America,” but that comparison only scratches the surface of its business model. The company operates a comprehensive ecosystem that includes e-commerce, digital payments, logistics, and credit services.

The growth story for MercadoLibre is rooted in the ongoing digital transformation of Latin America. The region still has relatively low e-commerce and financial inclusion rates compared to developed markets, providing a long runway for expansion.

MercadoLibre Financial Performance

MercadoLibre delivered another strong quarter in Q4 2025, reinforcing its position as a high-growth company. Quarterly revenue reached $8.76 billion, representing a robust 44.56% year-over-year increase.

However, earnings per share (EPS) for the quarter came in at $11.03, marking a decline of 12.53% year over year. While this may raise concerns at first glance, the decline is largely attributable to increased investments in logistics infrastructure, technology, and customer acquisition strategic moves aimed at sustaining long-term growth rather than maximizing short-term profitability.

On a trailing twelve-month TTM basis, the company’s performance remains strong. Revenue reached $28.89 billion, up 39.06% year over year, demonstrating consistent top-line momentum. TTM EPS stood at $39.4, representing a modest but positive growth of 4.51%.

One of the most encouraging metrics is free cash flow per share, which surged to $212.5 on a TTM basis, up an impressive 52.64%.

Over the past five years, MercadoLibre has experienced rapid business growth, with free cash flow increasing significantly at high margins. E-commerce and fintech in Latin America remain underpenetrated, giving the company substantial room to grow.

MercadoLibre Fiscal 2026 Financial Forecast

Looking ahead, analyst expectations remain highly optimistic. Revenue is projected to reach $38.65 billion in 2026, representing a 33.79% increase from 2025 levels. Meanwhile, non-GAAP EPS is expected to grow to $49.7, a 26.13% increase year over year. These forecasts suggest that the company’s growth trajectory is far from over.

Wallstreet analysts currently assign a “Strong Buy” rating, with an average price target of $2,457, implying a potential upside of 33.9%. The highest price target stands at $3,500, suggesting a remarkable upside potential of 90.71%.

MELI Stock Price Performance and Valuation

Despite its strong fundamentals, MercadoLibre’s stock has faced headwinds in recent periods. At a share price of $1,835, the stock has declined 16.7% over the past year, significantly underperforming the S&P 500, which gained 30.6% during the same period.

Over a longer timeframe, the stock has also lagged. Over the past five years, MercadoLibre shares have risen 16.8%, compared to a 71.3% increase for the S&P 500. This underperformance may deter some investors, but it also creates a compelling opportunity as the valuation gets lower.

Based on Fiscal.ai data, valuations since 2023 show that the forward PS, forward PE, and PFCF are all below historical averages. This indicates potential undervaluation, especially as MercadoLibre continues to grow rapidly.

MercadoLibre Growth Potential

MercadoLibre growth potential remains solid, driven by several factors.

1. Accelerating Commerce Ecosystem and Market Share Gains

MercadoLibre’s commerce segment delivered strong Q4 2025 growth, with GMV reaching $19.9 billion up 37% YoY and rising items sold. Brazil and Mexico posted 35% FX-neutral GMV growth and 45% item growth, driven by lower free shipping thresholds and higher fulfillment penetration. Improved user engagement, record NPS, and low regional e-commerce penetration support long-term GMV expansion.

2. Rapid Fintech Expansion via Mercado Pago

Fintech was a key driver of Q4 performance, with TPV reaching $83.7 billion up 42% Year over year and nearly 78 million monthly active users growing around 30% for the 10th straight quarter. The credit portfolio nearly doubled to $12.5 billion, leveraging marketplace data for underwriting, strengthening a flywheel that boosts monetization and deepens user engagement across Latin America.

3. Underpenetrated Latin American Market with Ecosystem Flywheel

Latin America’s e-commerce and fintech markets remain underpenetrated, giving MercadoLibre significant growth runway as a leading integrated platform. Q4 marked roughly 28–29 consecutive quarters of 30%+ revenue growth, driven by strength across Brazil, Mexico, and Argentina. Its commerce-fintech-logistics flywheel, supported by network effects and 121 million buyers, enables high switching costs, resilience, and long-term GMV expansion.

Risks to Consider

While MercadoLibre looks like a good opportunity, we should be mindful of potential risks.

1. Intense Competition in E-commerce and Fintech

MercadoLibre contends with aggressive rivals including Shopee, Temu, Amazon, and local fintech players like Nubank. These competitors pressure pricing power, force higher marketing and logistics spend, and challenge market share in key markets like Brazil and Mexico. Sustained competition risks permanently resetting industry economics lower, eroding take rates and making it harder to maintain historical profitability levels.

2. Credit Portfolio and Fintech Risk Exposure

Rapid expansion of Mercado Crédito increases exposure to borrower defaults, especially amid economic volatility in Latin America. The credit book, still early in its seasoning cycle, heightens sensitivity to macro downturns, rising funding costs, and potential credit losses. As lending drives much of the fintech growth, any deterioration in asset quality or higher provisions for doubtful accounts could materially impact overall profitability and balance sheet strength.

3. Macroeconomic and Currency Volatility in Latin America

Operations across volatile economies, particularly Argentina with its history of hyperinflation and devaluations, expose MercadoLibre to currency translation losses and fluctuating local demand. Weak economic growth, political instability, and currency swings in Brazil, Mexico, and beyond can compress USD-reported revenues and earnings, even when local-currency performance holds steady. These regional risks remain a persistent drag on financial predictability.

Despite this, MercadoLibre’s lower valuation compared to its historical levels especially in free cash flow, makes it an attractive stock to buy.

3. Zevra Therapeutics

Zevra Therapeutics represents a different kind of growth opportunity, one that comes with higher risk but potentially significant rewards. The company focuses on developing treatments for rare diseases, a niche that can offer substantial pricing power and regulatory advantages.

Unlike established pharmaceutical companies, Zevra is still in the early stages of commercialization. Its business model revolves around advancing drug candidates through clinical trials and securing regulatory approvals. This means its success is highly dependent on the outcomes of its pipeline.

Zevra Financial Performance

Zevra Therapeutics delivered standout financial results in Q4 2025, showcasing both rapid growth and improving operational efficiency.

For the quarter, the company reported revenue of $34.13 million, representing a remarkable 183.36% year-over-year increase. This surge reflects strong product demand, successful commercialization strategies, and potentially expanded market access.

Profitability also improved significantly. Earnings per share (EPS) for Q4 2025 came in at $0.19, up 128.36% year over year.

On a trailing twelve-month TTM basis, Zevra’s performance is equally impressive. Revenue reached $106.47 million, representing a staggering 350.92% increase compared to the previous year. Meanwhile, TTM EPS stood at $1.33, up 159.38% year over year.

Over the past five years, Zevra has transitioned from a clinical-stage biotech company into a commercial-stage company and is now profitable. With its drug MIPLYFFA still in the early stages, Zevra is expected to continue growing rapidly in the coming years.

Zevra Fiscal 2026 Financial Forecast

Looking ahead, analysts remain optimistic about Zevra’s revenue trajectory. Forecasts for 2026 project revenue of $143.28 million, implying a 34.57% increase from 2025 levels.

However, there is a notable divergence when it comes to earnings expectations. Analysts forecast EPS of $0.49 for 2026, which represents a 63.95% decrease from 2025 levels. This anticipated decline is due to decrease from massive non-operating income in 2025.

Wallstreet analysts have assigned a Strong Buy rating, with an average price target of $22.78, suggesting a potential upside of 126% from current levels. The highest price target stands at $26, implying an even more optimistic upside of 157.94%. This bullish outlook underscores confidence in the company’s long-term growth story.

ZVRA Stock Price Performance and Valuation

Over the past year, Zevra Therapeutics has delivered solid returns for investors. At a current share price of $10.08, the stock has gained 39.2%, outperforming the broader S&P 500, which rose 30.6% during the same period. This outperformance reflects growing investor confidence in the company’s fundamentals and future prospects.

However, the longer-term picture is more nuanced. Over the past five years, Zevra’s stock has increased by just 3.6%, significantly underperforming the S&P 500’s 71.3% gain. This underperformance is not unusual for biotech firms, especially those transitioning from development stages to commercialization.

From a valuation perspective, the stock is currently trading at a forward PS of 4.2 and a forward PE of 20.3, which appears reasonable and undervalued compared to its growth projection.

Zevra Growth Potential

Zevra growth potential remains strong, driven by several factors.

1. Strong Revenue Momentum from MIPLYFFA Launch

Zevra delivered strong growth in 2025, with net revenue rising to $106.5 million from $23.6 million in 2024, largely driven by MIPLYFFA’s $87.4 million contribution. Q4 revenue reached $34.1 million, up 31% Quarter over quarter. Growing U.S. traction in the rare Niemann-Pick disease type C NPC market, expanding patient adoption, and improving access support continued double-digit growth potential.

2. Geographic and Access Expansion Opportunities

Zevra expanded beyond the U.S. through its global Expanded Access Program EAP, generating $13 million in 2025 reimbursements, including $5.6 million in Q4, and supporting 113 patients. New distribution agreements enabled broader shipments. Meanwhile, MIPLYFFA’s European Medicines Agency  EMA application remains under review, potentially unlocking new revenue streams, expanding the NPC patient base, and reducing reliance on U.S. sales concentration.

3. Late-Stage Pipeline Progress for Diversification

Zevra is advancing celiprolol in its Phase 3 DiSCOVER trial for VEDS, reaching 52 patients by end-2025 with early event tracking underway and FDA engagement on acceleration options. Alongside MIPLYFFA real-world data and potential U.S. patent-term extension to 2031, the pipeline supports long-term growth, offering a second potential commercial asset and reducing single-product dependence in rare diseases.

Risks to Consider

While Zevra looks like a promising biotech stock, we should be mindful of potential risks.

1. Commercial Launch and Market Adoption Risks

Zevra faces challenges in driving sustained uptake for its approved therapies in ultra-rare disease markets. MIPLYFFA has shown strong initial revenue growth, but slow prescription enrollment for OLPRUVA highlights potential difficulties in physician awareness, patient diagnosis, and real-world adoption. Limited patient pools in Niemann-Pick type C and urea cycle disorders could constrain revenue scaling if market penetration falls short of expectations.

2. Reimbursement and Payer Coverage Challenges

Poor or inconsistent payer coverage remains a significant hurdle for rare disease drugs. Even with MIPLYFFA's commercial progress, delays in securing broad insurance reimbursement or unfavorable pricing negotiations could limit patient access and net sales. This risk is amplified in smaller patient populations where payers scrutinize cost-effectiveness, potentially impacting revenue forecasts and profitability timelines.

3. Regulatory and Pipeline Development Risks

Zevra’s growth hinges on regulatory approvals, including the EMA review of MIPLYFFA and progress of pipeline assets like celiprolol for vascular Ehlers-Danlos syndrome. Delays, data requests, or unfavorable decisions could limit international expansion, while clinical trial setbacks in ongoing studies such as Phase 3 Celiprolol add further execution risk and uncertainty to the company’s long-term outlook.

Despite this, Zevra’s transition into a profitable commercial biotech company, along with its reasonable valuation and expansion opportunities, makes it a compelling stock to own.

Read More: 3 Undervalued Stocks to Buy (AI, Fintech, Gold)

Conclusion

Broadcom, MercadoLibre, and Zevra Therapeutics each represent a unique pathway to high growth. Broadcom is a dominant player in AI infrastructure, benefiting from one of the most powerful technological trends of our time. MercadoLibre is capturing the digital transformation of an entire region, leveraging its ecosystem to drive sustained expansion. Zevra Therapeutics, meanwhile, offers a speculative but potentially lucrative opportunity in the biotech space. While their risk profiles differ, they all share strong growth drivers that could deliver significant long-term returns. But remember this is not a financial advice.